Baseline characteristics of 430 patients in study
| Characteristic . | Value . |
|---|---|
| Age, y | |
| Median | 71 |
| Range | 19-92 |
| Sex | |
| Male/female, % | 63/37 |
| Risk stratification by WHO,* n (%) | |
| Low risk | 250 (58) |
| High risk | 180 (42) |
| IPSS risk category, n (%) | |
| Low | 112 (26) |
| Int-1 | 124 (29) |
| Int-2 | 61 (14) |
| High | 44 (10) |
| Unclassified† | 89 (21) |
| WHO classification, n (%) | |
| MDS | |
| RCUD/RCMD | 114 (27) |
| RARS | 36 (8) |
| 5q− syndrome | 19 (4) |
| MDS-U | 8 (2) |
| RAEB1/2 | 73 (17) |
| MDS/MPN overlap | |
| CMML-1 | 36 (8) |
| CMML-2 | 18 (4) |
| MDS/MPN-U‡ | 41 (10) |
| sAML§ | 85 (20) |
| Characteristic . | Value . |
|---|---|
| Age, y | |
| Median | 71 |
| Range | 19-92 |
| Sex | |
| Male/female, % | 63/37 |
| Risk stratification by WHO,* n (%) | |
| Low risk | 250 (58) |
| High risk | 180 (42) |
| IPSS risk category, n (%) | |
| Low | 112 (26) |
| Int-1 | 124 (29) |
| Int-2 | 61 (14) |
| High | 44 (10) |
| Unclassified† | 89 (21) |
| WHO classification, n (%) | |
| MDS | |
| RCUD/RCMD | 114 (27) |
| RARS | 36 (8) |
| 5q− syndrome | 19 (4) |
| MDS-U | 8 (2) |
| RAEB1/2 | 73 (17) |
| MDS/MPN overlap | |
| CMML-1 | 36 (8) |
| CMML-2 | 18 (4) |
| MDS/MPN-U‡ | 41 (10) |
| sAML§ | 85 (20) |
RCUD indicates refractory anemia with unilineage dysplasia; RCMD, refractory cytopenia with multilineage dysplasia; RARS, refractory anemia with ring sideroblasts; MDS-U, myelodysplastic syndromes unclassified; RAEB-1/2, refractory anemia with excess blasts-1/2; CMML, chronic myelomonocytic leukemia; and MDS/MPN-U, myelodysplastic syndromes/myeloproliferative neoplasms unclassifiable.
Low risk includes RCUD, RARS, RCMD, CMML-1, MDS/MPN-U < 5% blasts, RARS-T, MDS-U, and 5q− syndrome. High risk includes RAEB-1/2, CMML-2, MDS/MPN-U ≥ 5% blasts, and AML.
Includes 28 cases of no growth and 61 cases that were not classified because they were CMML with white blood cell count > 12 000/μL, AML by WHO classification, and other factors precluding appropriate classification.
Sixteen cases of MDS/MPN-U are classified as RARS-T.
Thirty-four patients are classified as RAEB-T by French-American-British classification.